Healthcare payment software provider Waystar has spent 24 months turning a 2024 Nasdaq listing into one of the cleaner growth stories in healthcare fintech. The company priced its IPO at the low end of guidance in May 2024, listed under the ticker WAY, and raised roughly $968 million against an initial market cap near $3.7 billion. Today the picture looks materially different.
Q1 2026 revenue hit $313.9 million, up 22% year-on-year. Adjusted EBITDA reached $135.4 million on a 43% margin. The company guided full-year 2026 revenue to between $1.274 billion and $1.294 billion. Shares trade around $25, with the equity story now anchored to AI rather than the original revenue-cycle automation pitch.
Why the WAY listing redefined the category
Waystar arrived on the public market as the largest pure-play healthcare payment software provider Nasdaq had seen in years. The original S-1 leaned on a $760 billion to $935 billion wasteful-spending statistic from CMS-adjacent research, of which roughly $350 billion was tied to admin and billing inefficiency. The pitch was simple: take a slice of that backlog by automating claims, eligibility, denials, and patient payments.
That positioning held through 2024. The fintech IPO market had been frozen for two years before WAY priced, and the listing acted as a kind of pressure test for the entire enterprise-software-meets-payments thesis. The same selectivity is now showing up in other sector listings, including the European defense IPO surge, where public buyers want fundamentals before story.
Two years later, Waystar’s pricing power, retention, and AI roadmap give it a category-defining position rather than a fast-follower one. Net revenue retention ran at roughly 111% in Q1 2026, which is a strong number for any healthcare payment software provider operating at this scale.
Q1 2026 numbers and what they reveal
The mix tells the story. Subscription revenue hit $172.2 million in Q1 2026, up 38% year-on-year. Volume-based revenue came in at $139.5 million, up only 7%. The faster-growing line is the recurring software book, exactly what investors want from a healthcare payment software provider trying to look more like SaaS and less like a transaction processor.
Cash generation is doing its part too. Operating cash flow ran $84.9 million in Q1, with unlevered free cash flow at $90.3 million. Net income came in at $43.3 million, a 14% GAAP margin, while non-GAAP net income reached $81.2 million ($0.42 diluted).
That cash profile matters because it lets management invest in AI without leaning further on the balance sheet. For any healthcare payment software provider integrating clinical and financial data, that distinction is now central to the investor pitch.
The Iodine bet and the AI pivot
The $1.25 billion Iodine Software acquisition closed in 2025 and remains the defining strategic move of the past two years. Iodine brought AI-powered clinical intelligence into the Waystar stack, expanding the addressable market by more than 15% and giving the platform mid-cycle visibility it previously lacked. Management said on the April 29 earnings call that the integration is running ahead of schedule.
AI capabilities drove roughly 40% of new bookings in Q1 2026. In April 2026, Waystar launched the industry’s first AI solution targeting “silent denials” from payer payment take-backs. The framing matters: Waystar wants to be the healthcare payment software provider that runs both billing and clinical-documentation workflows on a single platform.
That shift maps onto the broader question of whether AI super-apps will turn banks into back-end plumbing. In healthcare, the back-end plumbing is exactly where the margin sits, and Waystar wants to own it. The healthcare payment software provider category is consolidating around platforms, while point solutions are losing momentum.
Margins, leverage, and the bear case
Real risks sit under the surface. Net debt at March 31, 2026 stood at $1.32 billion, mostly from the Iodine deal. The adjusted net leverage ratio sits at 2.7x trailing adjusted EBITDA, which is manageable but not trivial.
Patient payment volumes also softened in Q1 because of macro and weather-related dynamics, dragging volume-based revenue growth to just 7%. If providers tighten budgets, the volume line gets squeezed first. The leverage profile leaves limited room for a prolonged volume drought without margin pressure.
Margin expansion is the other variable. Trailing twelve-month net margin moved from 2.7% to 10.9%, a real step up, though bullish narratives that talk about mid-20s margins are not yet supported by the numbers. The 43% adjusted EBITDA margin is the headline, but GAAP margins are still doing the harder work of catching up.
Fraud and denial management sit closely related to the B2B payments fraud gaps that boards across the sector are racing to close. Waystar’s pitch is that its platform closes those gaps for providers rather than for banks.
5 healthcare payment software provider signals investors should track
Signal one: subscription revenue is outpacing volume revenue by a wide margin. A healthcare payment software provider with this mix earns a software multiple, not a processor multiple.
Next, AI bookings already represent 40% of new wins. The Iodine acquisition is paying off in real-time pipeline metrics rather than slide-deck promises.
Net revenue retention above 110% is the third signal. Existing customers are spending more each year, and for any healthcare payment software provider, that is the cleanest evidence of pricing power.
Cash flow tells the fourth story. Operating cash comfortably funds the AI roadmap without forcing new debt, and net leverage at 2.7x is steady rather than rising.
The fifth and possibly most important: management’s 2026 guidance midpoint of roughly $1.28 billion implies high-teens growth even after the Iodine boost normalises. That is the bar every healthcare payment software provider listing since 2024 has tried to clear, and Waystar is one of the few clearing it on guidance rather than hope.
For investors evaluating any healthcare payment software provider in the public market today, the WAY trajectory remains the closest reference comp. The platform, the AI moat, and the margin path now matter more than the original 2024 thesis about claims automation. The story has matured, and so has the stock.
The same investor selectivity that shaped Waystar’s 2024 debut is now reshaping other categories, including the infrastructure layer behind real-time payment rails for SMB cash flow. The cleanest read on the WAY trajectory, then, is that scale plus AI is winning, and Waystar is the listing investors keep coming back to for evidence.
